Several SYK inhibitors such as fostamatinib and entospletinib are under clinical development primarily for hematologic disorders and B lymphocyte malignancies, with fostamatinib being first approved for the treatment of immune thrombocytopenia (28, 29). Here, SYK is linked to hematologic disorder.